Market accessOfficial

MSD to end Emend (aprepitant) marketing in EU/EEA; Italy's 125 mg + 80 mg capsules go from 30 November

🇮🇹 AIFA · Mon 16 Nov 2026

AIFA says the withdrawal is commercial and unrelated to safety, efficacy or quality, and asks healthcare professionals to review ongoing treatment plans.

The Italian Medicines Agency (AIFA) published a notice on 16 November 2026 on the definitive cessation of marketing of Emend (aprepitant). MSD Italia S.r.l., the local representative of Merck Sharp & Dohme B.V., told AIFA and other European regulators that the product will permanently leave the market in the European Union and European Economic Area.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Official source: AIFA ↗

Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.